Invention Grant
- Patent Title: Anti-DLL3 antibody
-
Application No.: US14846135Application Date: 2015-09-04
-
Publication No.: US11111311B2Publication Date: 2021-09-07
- Inventor: Kenji Yoshida , Hiroyuki Aburatani , Shumpei Ishikawa
- Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA , THE UNIVERSITY OF TOKYO
- Applicant Address: JP Tokyo; JP Tokyo
- Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA,THE UNIVERSITY OF TOKYO
- Current Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA,THE UNIVERSITY OF TOKYO
- Current Assignee Address: JP Tokyo; JP Tokyo
- Agency: Sughrue Mion, PLLC
- Priority: JPJP2010-019391 20100129
- Main IPC: C07K16/30
- IPC: C07K16/30 ; C07K16/28 ; A61K39/395 ; A61K39/00 ; C12Q1/6886 ; G01N33/574
Abstract:
It is intended to disclose an antibody which binds to DLL3 protein. Preferably, the antibody of the present invention recognizes a region from amino acids 216 to 492 in human DLL3 having the amino acid sequence as set forth in SEQ ID NO: 1. The present invention also provides a pharmaceutical composition, for example, an anticancer agent, comprising the antibody of the present invention as an active ingredient. The present invention further discloses a method for diagnosing cancer using the antibody of the present invention and a diagnostic drug for cancer comprising the antibody of the present invention.
Public/Granted literature
- US20160244530A2 ANTI-DLL3 ANTIBODY Public/Granted day:2016-08-25
Information query
